JP2014526447A5 - - Google Patents

Download PDF

Info

Publication number
JP2014526447A5
JP2014526447A5 JP2014528879A JP2014528879A JP2014526447A5 JP 2014526447 A5 JP2014526447 A5 JP 2014526447A5 JP 2014528879 A JP2014528879 A JP 2014528879A JP 2014528879 A JP2014528879 A JP 2014528879A JP 2014526447 A5 JP2014526447 A5 JP 2014526447A5
Authority
JP
Japan
Prior art keywords
nasal
nose
carrier material
powder
inhaled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014528879A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014526447A (ja
JP6060163B2 (ja
Filing date
Publication date
Priority claimed from DE102011112978A external-priority patent/DE102011112978A1/de
Application filed filed Critical
Publication of JP2014526447A publication Critical patent/JP2014526447A/ja
Publication of JP2014526447A5 publication Critical patent/JP2014526447A5/ja
Application granted granted Critical
Publication of JP6060163B2 publication Critical patent/JP6060163B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014528879A 2011-09-09 2012-08-13 キナーゼインヒビターとしてのベンゾニトリル誘導体 Expired - Fee Related JP6060163B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102011112978.6 2011-09-09
DE102011112978A DE102011112978A1 (de) 2011-09-09 2011-09-09 Benzonitrilderivate
PCT/EP2012/003449 WO2013034238A1 (de) 2011-09-09 2012-08-13 Benzonitrilderivate als kinasehemmer

Publications (3)

Publication Number Publication Date
JP2014526447A JP2014526447A (ja) 2014-10-06
JP2014526447A5 true JP2014526447A5 (https=) 2015-10-01
JP6060163B2 JP6060163B2 (ja) 2017-01-11

Family

ID=46679243

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014528879A Expired - Fee Related JP6060163B2 (ja) 2011-09-09 2012-08-13 キナーゼインヒビターとしてのベンゾニトリル誘導体

Country Status (27)

Country Link
US (1) US8969335B2 (https=)
EP (1) EP2753615B1 (https=)
JP (1) JP6060163B2 (https=)
KR (1) KR101985984B1 (https=)
CN (1) CN103930416B (https=)
AR (1) AR087807A1 (https=)
AU (1) AU2012306746B2 (https=)
BR (1) BR112014005226A2 (https=)
CA (1) CA2848148C (https=)
DE (1) DE102011112978A1 (https=)
DK (1) DK2753615T3 (https=)
EA (1) EA025038B1 (https=)
ES (1) ES2644128T3 (https=)
HR (1) HRP20171296T1 (https=)
HU (1) HUE036774T2 (https=)
IL (1) IL231382A (https=)
IN (1) IN2014KN00769A (https=)
LT (1) LT2753615T (https=)
MX (1) MX344335B (https=)
NO (1) NO2753615T3 (https=)
PL (1) PL2753615T3 (https=)
PT (1) PT2753615T (https=)
RS (1) RS56481B1 (https=)
SG (1) SG2014015234A (https=)
SI (1) SI2753615T1 (https=)
WO (1) WO2013034238A1 (https=)
ZA (1) ZA201402561B (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2852584B1 (en) 2012-05-22 2018-02-28 F. Hoffmann-La Roche AG Substituted dipyridylamines and uses thereof
GB201303109D0 (en) 2013-02-21 2013-04-10 Domainex Ltd Novel pyrimidine compounds
CA2907912A1 (en) 2013-05-01 2014-11-06 F. Hoffmann-La Roche Ag C-linked heterocycloalkyl substituted pyrimidines and their uses
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
TW201613916A (en) 2014-06-03 2016-04-16 Gilead Sciences Inc TANK-binding kinase inhibitor compounds
CN104201295B (zh) * 2014-09-16 2017-05-03 深圳市华星光电技术有限公司 Oled的封装方法及oled结构
NZ729618A (en) 2014-09-26 2018-07-27 Gilead Sciences Inc Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds
US9994547B2 (en) 2014-10-06 2018-06-12 Takeda Pharmaceutical Company Limited Heteroarylamide inhibitors of TBK1
CN106854174A (zh) * 2015-12-08 2017-06-16 湖南华腾制药有限公司 一种4位取代哌啶衍生物的制备方法
EP3394044A1 (en) * 2015-12-17 2018-10-31 Gilead Sciences, Inc. Tank-binding kinase inhibitor compounds
WO2017102091A1 (en) 2015-12-18 2017-06-22 Bayer Pharma Aktiengesellschaft Heteroarylbenzimidazole compounds
CN107286076A (zh) * 2016-04-05 2017-10-24 湖南华腾制药有限公司 一种哌啶类化合物的制备方法
CN107400082A (zh) * 2016-05-19 2017-11-28 湖南华腾制药有限公司 一种取代哌啶衍生物的制备方法
WO2017207534A1 (en) 2016-06-03 2017-12-07 Bayer Pharma Aktiengesellschaft Substituted heteroarylbenzimidazole compounds
DE102016113714A1 (de) 2016-07-26 2018-02-01 Rosa Karl Transfektionsverfahren mit nicht-viralen Genliefersystemen
CN107698491A (zh) * 2016-08-08 2018-02-16 湖南华腾制药有限公司 一种取代哌啶衍生物的制备方法
CN107778216A (zh) * 2016-08-30 2018-03-09 湖南华腾制药有限公司 一种氟取代哌啶衍生物的制备方法
CN107778215A (zh) * 2016-08-30 2018-03-09 湖南华腾制药有限公司 一种氟取代哌啶衍生物的制备方法
CN108117510A (zh) * 2016-11-29 2018-06-05 湖南华腾制药有限公司 一种哌啶衍生物的制备方法
CN108610309A (zh) * 2016-12-13 2018-10-02 湖南华腾制药有限公司 一种哌啶衍生物的制备方法
GB201702947D0 (en) 2017-02-23 2017-04-12 Domainex Ltd Novel compounds
US20230019491A1 (en) * 2017-10-17 2023-01-19 Srinivasa R. Karra PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
BR112020007549A2 (pt) * 2017-10-17 2020-09-24 Merck Patent Gmbh compostos inibidores de pirimidina tbk/ikképsilon e uso dos mesmos
WO2020118683A1 (en) * 2018-12-14 2020-06-18 Lynk Pharmaceuticals Co. Ltd. Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
WO2020206588A1 (en) * 2019-04-08 2020-10-15 Lynk Pharmaceuticals Co., Ltd. Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
CN110627775B (zh) * 2019-10-24 2026-01-30 特科罗生物科技(成都)有限公司 一种小分子化合物
CN112209886A (zh) * 2020-11-09 2021-01-12 沈阳药科大学 2-(3-氰基-4-烷氧基)苯基嘧啶衍生物及其制备方法和用途
CN113024565B (zh) * 2021-03-31 2022-09-13 上海启甄环境科技有限公司 一种放射性同位素碳-14标记依鲁替尼及其合成方法
WO2024239282A1 (zh) * 2023-05-24 2024-11-28 凌科药业(杭州)有限公司 一种药物组合物、外用制剂及其制备方法、应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
MXPA05001804A (es) * 2002-08-14 2005-05-27 Vertex Pharma Inhibidores de proteinas cinasas y usos de los mismos.
SE0203754D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
EP1648875A1 (en) 2003-07-30 2006-04-26 Cyclacel Limited 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
EP2016075A1 (en) 2006-05-03 2009-01-21 AstraZeneca AB Thiazole derivatives and their use as anti-tumour agents
WO2008065155A1 (en) 2006-11-30 2008-06-05 Ingenium Pharmaceuticals Gmbh Cdk inhibitors for treating pain
HRP20151386T1 (hr) 2007-03-12 2016-02-26 Ym Biosciences Australia Pty Ltd Fenil aminopirimidinski spojevi i njihova primjena
WO2009030890A1 (en) 2007-09-03 2009-03-12 University Court Of The University Of Dundee Pyrimidine compounds for the treatment of cancer, septic shock and/or primary open angle glaucoma
US8530480B2 (en) 2007-09-04 2013-09-10 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors
ATE523508T1 (de) 2007-10-25 2011-09-15 Astrazeneca Ab Für die behandlung von zellproliferativen erkrankungen geeignete pyridin- und pyrazinderivate
WO2009122180A1 (en) 2008-04-02 2009-10-08 Medical Research Council Pyrimidine derivatives capable of inhibiting one or more kinases
GB0903759D0 (en) 2009-03-04 2009-04-15 Medical Res Council Compound
WO2010151747A1 (en) * 2009-06-26 2010-12-29 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimine compounds and methods of making and using same
WO2011046970A1 (en) 2009-10-12 2011-04-21 Myrexis, Inc. Amino - pyrimidine compounds as inhibitors of tbkl and/or ikk epsilon
GB201012105D0 (en) 2010-07-19 2010-09-01 Domainex Ltd Novel pyrimidine compounds
AU2011328237A1 (en) 2010-11-09 2013-05-23 Cellzome Limited Pyridine compounds and aza analogues thereof as TYK2 inhibitors
WO2012142329A1 (en) * 2011-04-12 2012-10-18 Myrexis, Inc. Compositions and therapeutic uses of ikk-related kinase epsilon and tankbinding kinase 1 inhibitors

Similar Documents

Publication Publication Date Title
JP2014526447A5 (https=)
JP2013544781A5 (https=)
JP2014509313A5 (https=)
JP2013534227A5 (https=)
JP2015505541A5 (https=)
JP2013541565A5 (https=)
Weber et al. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for pulmonary application: a review of the state of the art
Doktorovova et al. Preclinical safety of solid lipid nanoparticles and nanostructured lipid carriers: Current evidence from in vitro and in vivo evaluation
Yang et al. Pulmonary drug delivery by powder aerosols
EA201590286A1 (ru) Аэрозольное ингаляционное устройство
WO2014074797A8 (en) Ultra low density pulmonary powders
TN2015000395A1 (en) Respirable agglomerates of porous carrier particles and micronized drug
UA112296C2 (uk) Сухий порошковий препарат, який містить інгібітор фосфодіестерази
IN2014DN09377A (https=)
AR098640A1 (es) Inhalador de polvo seco
WO2012024595A3 (en) Circumferential aerosol device for delivering drugs to olfactory epithelium and brain
UA107499C2 (uk) Склад сухого порошку, який містить антимускариновий засіб
PH12012500631A1 (en) Improvements to pressurised metered dose inhalers
MY191380A (en) Stabilized fixed dose drug composition having mometasone and olopatadine
EA201401354A1 (ru) Новая дозированная форма и препарат, содержащий абедитерол
EP4233874A3 (en) Acetylsalicylic acid for reducing the risk of a thromboembolic event
EA201590734A8 (ru) Вдыхаемые лекарственные средства
EA201700182A1 (ru) Состав для повышения стабильности лекарственного препарата, содержащий по меньшей мере один сухой порошок, полученный распылительной сушкой
JP2004534813A5 (https=)
EA201591415A1 (ru) Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии